OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🟢 Outlook Therapeutics is trading 14.8% up
Outlook Therapeutics is trading at $1.78, up 14.8% from a comparison close of $1.55 during regular trading. This is a price-action follow-up, so a separate...
Outlook Therapeutics Rallies Toward FDA Decision Day — But Can a 17-Person Company Turn One Drug Into a Real Business?
Shares of Outlook Therapeutics surged 12.3% to $1.74 on July 14, defying broader biotech weakness as traders pile into the stock ahead of a make-or-break FDA...
🟢 Outlook Therapeutics is trading 8.5% up today on positioning ahead of FDA decision for Lytenava
Outlook Therapeutics is trading 8.5% up at $1.74 as traders continue to position ahead of the upcoming FDA decision on its eye drug Lytenava. • The upward...
🔴 Outlook Therapeutics is trading 5.65% down today on profit-taking after recent PDUFA-driven rally
Outlook Therapeutics is trading at $1.58 (5.65% down) as the stock experiences a pullback following a sharp multi-day run-up. • The recent rally was fueled...
🟢 Outlook Therapeutics is trading 10.1% up
Outlook Therapeutics is trading at $1.86, up 10.1% from a comparison close of $1.69 during regular trading. This is a price-action follow-up, so a separate...
🟢 Outlook Therapeutics is trading 6.2% up today on FDA acceptance of BLA for ONS-5010
Outlook Therapeutics is trading 6.2% up at $1.81 as investors position ahead of a key regulatory milestone for its lead retinal therapy. • The FDA has...
🟢 OTLK makes sharp 13.7% jump
OTLK is trading at $1.66, up 13.7% versus the comparison close of $1.46 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 OTLK is trading 6.2% up today on positioning ahead of July FDA decision
OTLK is trading 6.2% up today at $1.55 on follow-through positioning ahead of a July FDA action date for its wet-AMD drug, Lytenava. • The move extends a mild...
🟢 OTLK is trading 5.7% up today on continued momentum from FDA appeal victory and BLA resubmission
OTLK is trading 5.7% up at $1.53 following a recent FDA appeal victory and the June 1 BLA resubmission for ONS-5010 (Lytenava). • The FDA confirmed that...
🟢 OTLK is trading 7.8% up today with no clear company-specific catalyst
OTLK is trading 7.8% up now at $1.58 after two weak sessions and recent volatility around the $1.50–$1.70 range. No fresh company-specific news, earnings, FDA...
🔴 OTLK down 5% today following recent rally fueled by FDA BLA acceptance and Nasdaq compliance
• OTLK is trading 5% down at $1.60 today, likely due to profit-taking after its recent rally. • The rally was driven by the FDA's acceptance of the resubmitted...
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Outlook Therapeutics, Inc. has received notification from Nasdaq confirming that it has regained compliance with the minimum bid price requirement for...
🟢 OTLK makes sharp 10.9% jump
OTLK is trading at $1.78, up 10.9% versus the comparison close of $1.61 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 OTLK is trading 7.1% up today as it rebounds from profit-taking following FDA BLA acceptance
OTLK is trading 7.1% up at $1.73, rebounding after yesterday’s profit-taking dip that followed a sharp rally driven by regulatory progress. • The primary...
🔴 OTLK is trading 5.1% down today as traders take profits following its recent FDA-driven rally
OTLK is trading at $1.59 (down 5.1%) as the stock experiences a pullback following a significant rally sparked by positive regulatory news. • The recent surge...
🔴 OTLK is trading 5.2% down today as the recent FDA-driven rally cools
OTLK is trading at $1.61 (-5.24%) today as the stock gives back part of its recent gains following the FDA's acceptance of its resubmitted BLA. • The FDA has...
Outlook Therapeutics Nears Its Make-or-Break FDA Moment — But Can a Cash-Strapped Micro-Cap Actually Sell Its Eye Drug?
Shares of Outlook Therapeutics edged up 1.8% in pre-market to $1.73, extending a rally that has seen the stock roughly triple from its March lows. The...
🟢 OTLK is trading 1.8% up today after FDA sets July 2026 decision date for Lytenava
OTLK is trading 1.8% up at $1.73 in pre-market trading following enthusiasm around the FDA’s July 29, 2026, PDUFA date for its eye drug Lytenava. • The FDA...
🟢 OTLK is trading 1.8% up today after FDA sets July decision date for Lytenava
OTLK is trading at $1.73 (+1.8%) in pre-market, continuing a rally sparked by the FDA setting a July decision date for its eye drug, Lytenava. • The FDA...
🔴 OTLK is trading 6.3% down today on profit-taking after a recent multi-day surge
OTLK is trading 6.3% down at $1.72 as investors lock in profits following a sharp multi-session rally. • The stock recently experienced significant upward...